ArticleJournal of clinical medicine2020
Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation.
Open access · goldAbstract read
In one paragraph
Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Deciphering the Role of microRNAs: Unveiling Clinical Biomarkers and Therapeutic Avenues in Atrial Fibrillation and Associated Stroke-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Exosomal lncRNA XR_001793654.1 in human cardiac explant-derived alleviates atrial fibrillation via abolishing the miR-107-3p-mediated KLF13 inhibition.Frontiers in cell and developmental biology · 2025Article
- MicroRNAs in atrial fibrillation - have we discovered the Holy Grail or opened a Pandora's box?Frontiers in pharmacology · 2025Review
- MicroRNAs in Atrial Fibrillation: Mechanisms, Vascular Implications, and Therapeutic Potential.Biomedicines · 2024Review
- M2 macrophage‑derived exosomes alleviate KCa3.1 channel expression in rapidly paced HL‑1 myocytes via the NF‑κB (p65)/STAT3 signaling pathway.Molecular medicine reports · 2024Article
- Impaired regulation of MMP2/16-MLCK3 by miR-146a-5p increased susceptibility to myocardial ischaemic injury in aging mice.Cardiovascular research · 2023Article
- Integrative identification of hub genes in development of atrial fibrillation related stroke.PloS one · 2023Article
- microRNAs as biomarkers of risk of major adverse cardiovascular events in atrial fibrillation.Frontiers in cardiovascular medicine · 2023Review
- MiR-32-3p Regulates Myocardial Injury Induced by Microembolism and Microvascular Obstruction by Targeting RNF13 to Regulate the Stability of Atherosclerotic Plaques.Journal of cardiovascular translational research · 2022Article
- Role of Cardiomyocyte-Derived Exosomal MicroRNA-146a-5p in Macrophage Polarization and Activation.Disease markers · 2022Article
- Redox-related biomarkers in human cardiovascular disease - classical footprints and beyond.Redox biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
José Miguel Rivera-CaravacaDepartment of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, 30120 Murcia, Spain.ORCID 0000-0003-0492-6241
Raúl Teruel-MontoyaDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.ORCID 0000-0002-6741-9725
Vanessa RoldánDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.ORCID 0000-0002-4945-6602
Rosa Cifuentes-RiquelmeDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.
José Antonio Crespo-MatasDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.
Ascensión María de Los Reyes-GarcíaDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.ORCID 0000-0002-9194-2348
Sonia ÁguilaDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.
María Piedad Fernández-PérezDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.
Laura Reguilón-GallegoDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.
Laura Zapata-MartínezDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.
Nuria García-BarberáDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.
Vicente VicenteDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.ORCID 0000-0002-4278-3264
Francisco MarínDepartment of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, 30120 Murcia, Spain.
Constantino MartínezDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.ORCID 0000-0002-2976-2354
Rocío González-ConejeroDepartment of Hematology and Medical Oncology, Hospital General Universitario Morales Meseguer, University of Murcia, Centro Regional de Hemodonación, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), 30003 Murcia, Spain.ORCID 0000-0002-4772-9822
Hospital General Universitario Morales Meseguer · ESCentro de Investigación en Red en Enfermedades Cardiovasculares · ES
Funding
Fundación Séneca 19873/GERM/15Instituto de Salud Carlos III PI17/00051
Abstract
PubMed holds no abstract for this paper.
Indexed as
2MACEadverse cardiovascular eventatrial fibrillationmiRNAsrisk stratification
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.